We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Catalyst Pharmaceutical (CPRX - Free Report) will announce quarterly earnings of $0.42 per share in its forthcoming report, representing a decline of 40% year over year. Revenues are projected to reach $140.02 million, declining 1.3% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Catalyst metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to come in at $96.43 million. The estimate indicates a change of +16.9% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product revenue, Net- FYCOMPA' will reach $12.28 million. The estimate suggests a change of -67.9% year over year.
According to the collective judgment of analysts, 'Revenues- Product revenue, Net- AGAMREE' should come in at $31.30 million. The estimate indicates a year-over-year change of +48.5%.
The average prediction of analysts places 'Revenues- Product revenue,net' at $140.01 million. The estimate indicates a year-over-year change of -1.3%.
Over the past month, Catalyst shares have recorded returns of +0.5% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #3 (Hold), CPRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Catalyst Pharmaceutical (CPRX - Free Report) will announce quarterly earnings of $0.42 per share in its forthcoming report, representing a decline of 40% year over year. Revenues are projected to reach $140.02 million, declining 1.3% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Catalyst metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to come in at $96.43 million. The estimate indicates a change of +16.9% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product revenue, Net- FYCOMPA' will reach $12.28 million. The estimate suggests a change of -67.9% year over year.
According to the collective judgment of analysts, 'Revenues- Product revenue, Net- AGAMREE' should come in at $31.30 million. The estimate indicates a year-over-year change of +48.5%.
The average prediction of analysts places 'Revenues- Product revenue,net' at $140.01 million. The estimate indicates a year-over-year change of -1.3%.
View all Key Company Metrics for Catalyst here>>>Over the past month, Catalyst shares have recorded returns of +0.5% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #3 (Hold), CPRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .